Hospital Universitari Arnau de Vilanova, Universitat de Lleida, IRBLLEIDA, CIBERONC, Lleida, Spain.
Hospital Universitari de Bellvitge, IDIBELL, Barcelona, Spain.
Virchows Arch. 2019 May;474(5):585-598. doi: 10.1007/s00428-018-02516-2. Epub 2019 Feb 1.
The two most frequent types of endometrial cancer (EC) are endometrioid (EEC) and serous carcinomas (SC). Differential diagnosis between them is not always easy. A subset of endometrial cancers shows misleading microscopical features, which cause problems in differential diagnosis, and may be a good scenario for next-generation sequencing. Previous studies have assessed the usefulness of targeted sequencing with panels of generic cancer-associated genes in EC histological typing. Based on the analysis of TCGA (The Cancer Genome Atlas), EEC and SC have different mutational profiles. In this proof of principle study, we have performed targeted sequencing analysis with a customized panel, based on the TCGA mutational profile of EEC and SC, in a series of 24 tumors (16 EEC and 8 SC). Our panel comprised coding and non-coding sequences of the following genes: ABCC9, ARID1A, ARID5B, ATR, BCOR, CCND1, CDH19, CHD4, COL11A1, CSDE1, CSMD3, CTCF, CTNNB1, EP300, ERBB2, FBXW7, FGFR2, FOXA2, KLLN, KMT2B, KRAS, MAP3K4, MKI67, NRAS, PGAP3, PIK3CA, PIK3R1, PPP2R1A, PRPF18, PTEN, RPL22, SCARNA11, SIN3A, SMARCA4, SPOP, TAF1, TP53, TSPYL2, USP36, and WRAP53. Targeted sequencing validation by Sanger sequencing and immunohistochemistry was performed in a group of genes. POLE mutation status was assessed by Sanger sequencing. The most mutated genes were PTEN (93.7%), ARID1A (68.7%), PIK3CA (50%), and KMT2B (43.7%) for EEC, and TP53 (87.5%), PIK3CA (50%), and PPP2R1A (25%) for SC. Our panel allowed correct classification of all tumors in the two categories (EEC, SC). Coexistence of mutations in PTEN, ARID1A, and KMT2B was diagnostic of EEC. On the other hand, absence of PTEN, ARID1A, and KMT2B mutations in the presence of TP53 mutation was diagnostic of SC. This proof of concept study demonstrates the suitability of targeted sequencing with a customized endometrial cancer gene panel as an additional tool for confirming histological typing.
子宫内膜癌(EC)最常见的两种类型是子宫内膜样癌(EEC)和浆液性癌(SC)。它们之间的鉴别诊断并不总是容易的。一小部分子宫内膜癌显示出具有误导性的显微镜特征,这在鉴别诊断中会造成问题,并且可能是下一代测序的一个很好的应用场景。先前的研究已经评估了在 EC 组织学分型中使用针对通用癌症相关基因的面板进行靶向测序的有用性。基于 TCGA(癌症基因组图谱)的分析,EEC 和 SC 具有不同的突变特征。在这项原理验证研究中,我们针对 EEC 和 SC 的 TCGA 突变特征,使用定制的面板进行了靶向测序分析,该面板包含了以下基因的编码和非编码序列:ABCC9、ARID1A、ARID5B、ATR、BCOR、CCND1、CDH19、CHD4、COL11A1、CSDE1、CSMD3、CTCF、CTNNB1、EP300、ERBB2、FBXW7、FGFR2、FOXA2、KLLN、KMT2B、KRAS、MAP3K4、MKI67、NRAS、PGAP3、PIK3CA、PIK3R1、PPP2R1A、PRPF18、PTEN、RPL22、SCARNA11、SIN3A、SMARCA4、SPOP、TAF1、TP53、TSPYL2、USP36 和 WRAP53。通过 Sanger 测序和免疫组织化学对一组基因进行了靶向测序验证。通过 Sanger 测序评估 POLE 突变状态。EEC 中最常突变的基因是 PTEN(93.7%)、ARID1A(68.7%)、PIK3CA(50%)和 KMT2B(43.7%),而 SC 中最常突变的基因是 TP53(87.5%)、PIK3CA(50%)和 PPP2R1A(25%)。我们的面板能够正确分类这两类(EEC、SC)中的所有肿瘤。PTEN、ARID1A 和 KMT2B 突变的共存提示 EEC。另一方面,在存在 TP53 突变的情况下缺乏 PTEN、ARID1A 和 KMT2B 突变提示 SC。这项概念验证研究表明,使用定制的子宫内膜癌基因面板进行靶向测序作为确认组织学分型的辅助工具是合适的。